Know Cancer

or
forgot password

To Investigate Risk Factors of Radiation Pneumonitis, Fibrosis, and Impairment of Quality of Life by Radiotherapeutic Dosimetric and Biological Parameters for Lung Cancer Patients Receiving Thoracic Radiotherapy


N/A
18 Years
N/A
Open (Enrolling)
Both
Radiation Pneumonitis

Thank you

Trial Information

To Investigate Risk Factors of Radiation Pneumonitis, Fibrosis, and Impairment of Quality of Life by Radiotherapeutic Dosimetric and Biological Parameters for Lung Cancer Patients Receiving Thoracic Radiotherapy


We propose a prospective observational study to investigate the combinational effect of
radiotherapeutic dosimetric parameters [mean lung dose & percentage of lung volume receiving
at least 20Gy (V20)] and biological parameters [interleukin-6(IL6) & transforming growth
factor beta (TGFB)] in predicting radiation pneumonitis, fibrosis, and change of QoL among
at least fifty-three lung cancer patients. Eligibility included pathological or cytological
proven small cell or non small cell lung cancer, thoracic RT planned for more than 30Gy [if
fraction size >= 3Gy/fx] or 40Gy [if fraction size < 3 Gy/Fx], ECOG performance status [PS]
0-2, body weight loss [BWL] <=10% in previous 6 months, no prior thoracic RT and signed
informed consent prior to study entry. Basic pre-radiotherapy information will be collected,
which included BWL, ECOG PS, AJCC stage [I-IV], primary lesion site, history of
smoking/coexisting lung disease/dosage of chemotherapy/surgical resection, albumin level,
and pulmonary function test of FEV1/VC/DLCO(optional). Computed tomography [CT] of the whole
lung in treatment position with reference mark will be done for calculation of V20 and mean
lung dose. Blood test of IL6, TGFB by ELISA will be done before and after RT after storage
at -80℃. Bronchial-alveolar lavage test of IL6, TGFB by ELISA will be done before and after
RT if clinical available. Self-reported questionnaire [EORTC C30 & L13] will be collected
before and after RT and in every follow up visits after double-checked by trained
assistants. RT must be given by photon energies >=6MV. Radiation pneumonitis and fibrosis
will be assessed according to common toxicity criteria 3 [CTC-3] weekly during RT and in
every follow up visits. Chi-square test, logistic regression, and proportional hazard ratio
method will be used to investigate whether the parameter(s) can be effective in predicting
radiation related sequelae.


Inclusion Criteria:



- Non-pregnant adults (age >=20 y/o)

- Pathological or cytological proven small cell or non small cell lung cancer

- Thoracic RT planned for more than 30Gy [if fraction size >= 3Gy/fx] or 40Gy [if
fraction size < 3 Gy/Fx]

- ECOG PS 0-2

- Body weight loss <=10% in previous 6 months

Exclusion Criteria:

- prior thoracic RT

Type of Study:

Observational

Study Design:

Observational Model: Defined Population, Observational Model: Natural History, Time Perspective: Longitudinal, Time Perspective: Prospective

Principal Investigator

Chun-Ru Chien, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

National Taiwan University Hospital

Authority:

Taiwan: Department of Health

Study ID:

9261700803

NCT ID:

NCT00155909

Start Date:

July 2003

Completion Date:

June 2006

Related Keywords:

  • Radiation Pneumonitis
  • Radiation Pneumonitis
  • Radiotherapy Planning, Computer-Assisted
  • Pneumonia
  • Radiation Pneumonitis

Name

Location